Literature DB >> 18055227

Should we reconsider epilepsy surgery? The motivation of patients once rejected.

Maeike Zijlmans1, Erik Buskens, Maaike Hersevoort, Geertjan Huiskamp, Alexander C van Huffelen, Frans S S Leijten.   

Abstract

The pre-surgical work-up of patients with medically refractory epilepsy changes with the availability of new diagnostic procedures. New diagnostic investigations may also open up prospects for patients rejected in the past. A cohort of 71 Dutch patients rejected for epilepsy surgery 0.5-5 years earlier were approached to evaluate their willingness to undergo novel techniques. 64 (90%) responded to a questionnaire evaluating social and medical status, quality of life (QoL) and motivation to be reconsidered for epilepsy surgery. Four patients (6%) did not have seizures during the last 6 months. 56 patients (88%) were highly motivated to undergo new diagnostic procedures. Inability to localize the seizure focus had been the reason for rejection in 70% of these. We conclude that most patients once rejected for epilepsy surgery would like to benefit from novel techniques.

Entities:  

Mesh:

Year:  2007        PMID: 18055227     DOI: 10.1016/j.seizure.2007.10.006

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  4 in total

Review 1.  Methods and utility of EEG-fMRI in epilepsy.

Authors:  Louis André van Graan; Louis Lemieux; Umair Javaid Chaudhary
Journal:  Quant Imaging Med Surg       Date:  2015-04

2.  Quality of Life and Its Determinants in Adult Drug Refractory Epilepsy Patients Who Were Not Candidates for Epilepsy Surgery: A Correlational Study.

Authors:  Inder Puri; Deepa Dash; Madakasira Vasantha Padma; Manjari Tripathi
Journal:  J Epilepsy Res       Date:  2018-12-31

3.  Neuroimaging: just a collection of brain image files?

Authors:  Daniela Seixas; Margarida Ayres Basto
Journal:  Front Hum Neurosci       Date:  2009-12-11       Impact factor: 3.169

Review 4.  Present and future of simultaneous EEG-fMRI.

Authors:  Karin Rosenkranz; Louis Lemieux
Journal:  MAGMA       Date:  2010-01-26       Impact factor: 2.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.